Browse the evidence

Short-term testosterone replacement therapy (200mg intramuscular testosterone cypionate every 3 weeks for 6 months) significantly improves libido and reduces waist circumference in males with late-onset hypogonadism.

If you are a man over 50 with clinically diagnosed low testosterone, short-term testosterone replacement therapy (200mg every 3 weeks) can significantly improve your sex drive and reduce belly fat within 6 months. This study also found no dangerous spikes in prostate markers or blood thickness during this period, suggesting it can be safe with proper monitoring.

Fasted cardiovascular exercise is commonly recommended by bodybuilding coaches (67%), primarily to synergize with fat-burning supplements like yohimbine and clenbuterol, despite systematic reviews showing no superiority over fed cardio for fat loss in general populations.

Bodybuilding coaches frequently prescribe fasted cardio (67% of respondents) not because it burns more fat than fed cardio, but to allow the use of fat-burning supplements like yohimbine or clenbuterol. If you are not using these specific supplements, fasted cardio offers no fat-loss advantage over fed cardio. Focus on total weekly energy expenditure and recovery.

Diets high in rapidly digestible carbohydrates increase the insulin-to-glucagon ratio, shifting energy partitioning toward adipose storage and away from metabolically active tissues, which triggers compensatory hunger and reduced metabolic rate.

To manage weight, focus on reducing rapidly digestible carbohydrates (refined grains, added sugars) to lower insulin levels. This prevents the hormonal trapping of energy in fat cells and reduces the biological drive to overeat and slow metabolism.

High-glycemic load (GL) diets reduce total energy expenditure (TEE) compared to low-carbohydrate or low-GL diets, even when calories and weight are matched.

When maintaining weight loss, choose lower-carbohydrate or lower-glycemic load foods to support a higher metabolic rate compared to high-carbohydrate diets.

A 12-month Mediterranean diet intervention in firefighters leads to modest but significant improvements in specific cardiometabolic markers, specifically body fat percentage and LDL cholesterol, at 6 months, though these effects may not persist or reach significance after multiple comparison corrections.

While the diet improves adherence, expect modest changes in body fat and LDL cholesterol, particularly in the first 6 months. Do not expect dramatic shifts in these specific markers, and be aware that statistical significance may be lost when accounting for multiple health metrics.

Lifestyle interventions (diet and exercise) combined with GLP-1 receptor agonists (GLP-1RAs) may mitigate gastrointestinal side effects and enhance weight loss, though their efficacy requires confirmation via randomized controlled trials.

If you are taking a GLP-1RA, do not abandon lifestyle changes. Focus on dietary strategies like smaller, lower-fat meals to manage nausea and other side effects. This may help you stay on the medication longer and potentially achieve greater weight loss, although more research is needed to confirm these benefits.

Weight loss of 20% or higher with newer GLP-1RAs raises concerns for nutritional deficiency and sarcopenia, necessitating monitoring similar to post-bariatric surgery care.

If you are losing a lot of weight (20% or more) on a GLP-1RA, ask your doctor about monitoring for nutritional deficiencies and muscle loss. You may need a dietitian to help you ensure you are getting enough protein and nutrients, similar to post-bariatric surgery guidelines.

In obese patients with preexisting hip or knee osteoarthritis, GLP-1 receptor agonist use is associated with a significantly reduced odds of conversion to total joint arthroplasty (THA and TKA) within one year, independent of weight loss.

If you are obese and have existing hip or knee osteoarthritis, using a GLP-1 receptor agonist (like semaglutide or liraglutide) is associated with a lower risk of needing joint replacement surgery within a year, even if your weight doesn't change significantly. This suggests the drug may have direct protective effects on your joints, not just benefits from weight loss. Discuss this potential benefit with your doctor, especially if you are considering these medications for weight management or diabetes.

Bariatric surgery induces substantial and durable weight loss in adults with severe obesity, with 89.3% of patients achieving ≥20% weight loss in the short term (0-9 years) and 81.2% maintaining this loss in the long term (10-24 years).

For individuals with severe obesity (BMI ≥40 or ≥35 with health issues), bariatric surgery is the most effective method for achieving and maintaining significant weight loss. While lifestyle changes are crucial, they rarely result in the >20% weight loss seen with surgery. Surgery provides durable benefits for over a decade, making it a viable long-term solution for severe obesity.

GLP-1 receptor agonists (GLP-1RAs) promote significant weight loss and BMI reduction in people with HIV (PWH), with tirzepatide and longer treatment duration (>6 months) being the strongest predictors of achieving >5% weight loss.

If you have HIV and are struggling with weight gain, GLP-1 receptor agonists (like semaglutide or tirzepatide) are a proven, effective treatment option. The study shows that sticking with the medication for more than 6 months and reaching the maximum dose significantly increases your chances of losing more than 5% of your body weight. Tirzepatide, in particular, showed the strongest association with significant weight loss in this population.

Incorporating biological factors (hunger, satiety, metabolic adaptation) into social cognitive theory improves long-term weight loss maintenance compared to traditional behavioral interventions that ignore these biological drivers.

If you are struggling to maintain weight loss despite eating right and exercising, recognize that your body is likely fighting back with increased hunger and a slower metabolism. This is a biological response, not a failure of willpower. To succeed, you must manage these biological signals directly by prioritizing high-satiety foods (high protein, fiber, low energy density) and strategic meal timing, rather than relying solely on mental discipline or distraction techniques.

Discontinuation of GLP-1 analogues for obesity is primarily driven by side effects (36%), logistical challenges (24%), and cost (23%), leading to significantly lower long-term weight loss compared to persistent users.

If you are taking a GLP-1 for weight loss, sticking with it is the most important factor for success. Most people stop due to side effects, cost, or logistics, not because the drug doesn't work. To stay on it, work with your doctor to titrate the dose slowly to minimize stomach issues, seek financial assistance if the cost is prohibitive, and use telemedicine to reduce logistical burdens. Persisters lose significantly more weight (nearly 18%) than those who quit early (12.6%).

Optimizing the distribution of protein intake across meals, particularly by shifting protein from dinner to post-training snacks, can improve the efficiency of muscle protein synthesis (MPS) without increasing total daily protein needs.

You don't necessarily need to eat more protein, but you should spread it out. If you eat a huge dinner, try moving some of that protein to a snack immediately after your training session. This helps your body use the protein more effectively for muscle repair.

Supplementing meals with 3-4 grams of leucine can improve or normalize muscle protein synthesis in aging muscle, acting as a trigger for the mTOR pathway.

If you are older, adding 3-4 grams of leucine to your meals (or eating leucine-rich foods like beef or whey) can help trigger muscle growth. However, if you already eat enough protein, you might not need extra leucine supplements.

High adherence to a low-carbohydrate diet score is associated with significantly lower diastolic blood pressure, lower triglyceride concentrations, and higher HDL cholesterol in obese adults.

For obese adults, adopting a dietary pattern that lowers carbohydrate intake and increases fat intake (a high LCD score) is associated with better blood pressure and lipid profiles, specifically lower triglycerides and higher HDL. However, simply shifting macros may not reduce body weight if carbohydrate intake remains above 50% of total energy.

High adherence to a low-carbohydrate diet score is associated with a reduced prevalence of metabolic syndrome in obese adults.

Adhering to a low-carbohydrate dietary pattern is linked to a lower likelihood of having metabolic syndrome in obese individuals, likely due to improvements in blood pressure and lipids.

Eloralintide (LY3841136), a selective amylin receptor agonist, promotes significant body weight loss primarily through fat mass reduction with favorable gastrointestinal tolerability compared to non-selective amylin agonists.

Eloralintide is a once-weekly injection that targets specific receptors to reduce appetite and food intake. In early trials, it led to modest but significant weight loss (up to 4.4% in 4 weeks) primarily by burning fat, with fewer stomach side effects than some competitors. It is currently in early clinical stages and not yet widely available.

EULAR guidelines recommend early and aggressive screening and management of traditional cardiovascular disease (CVD) risk factors and metabolic syndrome components for all patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

If you have RA or PsA, ask your doctor about a comprehensive cardiovascular risk assessment, not just joint care. This includes checking for metabolic syndrome components (blood pressure, lipids, blood sugar, waist size). Follow EULAR guidelines which suggest aggressive management of these risks, potentially using medications like statins or newer diabetes drugs (SGLT2/GLP1) if appropriate, alongside lifestyle changes like quitting smoking and eating healthily.

Bodybuilding peak-week strategies involving carbohydrate supercompensation and acute water manipulation significantly increase the intracellular-to-extracellular water ratio (ICW/ECW) and phase angle, indicating fluid shifts from subcutaneous to intracellular compartments.

If you are a competitive bodybuilder, your peak week strategy of high carbohydrate intake combined with initial high water intake followed by a reduction can effectively shift water from under the skin into the muscles. This increases muscle fullness and definition (higher phase angle) even if your total body weight or total water volume decreases slightly. Monitor your bioelectrical impedance if possible to track this shift.

High carbohydrate intake (>60% of energy) is associated with higher all-cause mortality, whereas moderate intake (50-55% of energy) is associated with the lowest risk, forming a U-shaped relationship.

Aim for carbohydrates to make up about 50-55% of your daily energy intake. This moderate level is associated with the lowest risk of death in large global studies. Avoid diets that are either very high in carbs (>60%) or very low in carbs, as both extremes are linked to higher mortality. Focus on a balanced diet including fruits, vegetables, whole grains, and unprocessed meats.

Patients perceive lifestyle factors (diet, exercise) and biological factors (genetics, metabolism) as causes of obesity, but often lack understanding of the biological mechanisms, leading to a focus on willpower and emotional eating as primary determinants of weight loss maintenance.

Patients often believe that willpower and exercise are the main keys to keeping weight off, ignoring biological factors. This can lead to feelings of failure when willpower runs out. It is important to educate patients that biological factors also play a role, and that using medical interventions alongside lifestyle changes is valid and effective.

Patients perceive emotional eating, driven by stress, depression, and childhood adversity, as a significant cause of obesity and a barrier to weight loss maintenance.

For patients who eat in response to stress or depression, addressing the emotional root cause is crucial. Simply focusing on diet and exercise may not be enough. Psychological support and coping strategies can help manage emotional eating.

Even protein distribution is associated with lower-body muscular endurance, but not functional ability (gait speed or chair stand tests) in healthy women.

If your goal is muscular endurance (e.g., ability to perform repeated movements), spreading protein to meet relative targets (0.24 g/kg for <60yo, 0.4 g/kg for ≥60yo) per meal may help. However, do not expect this to directly improve your walking speed or daily functional tasks like chair stands if you are already healthy and active.

In people with type 2 diabetes, objectively assessed moderate-to-vigorous physical activity (MVPA) is inversely associated with systemic inflammatory markers IL-6, IL-1ra, and MCP-1, with the association being largely mediated by adiposity (BMI).

For people with Type 2 Diabetes, engaging in moderate-to-vigorous physical activity (like brisk walking) for just 10-minute increments daily is associated with lower levels of key inflammatory markers (IL-6, IL-1ra). While weight loss (BMI) plays a significant role in this benefit, the act of moving itself also reduces inflammation through non-weight-related mechanisms. Focus on consistent, moderate-intensity movement rather than just weight loss metrics.